Preventing HIV and achieving pregnancy among HIV sero-different couples: Pilot study of a safer conception intervention in Zimbabwe.


Journal

PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676

Informations de publication

Date de publication:
2023
Historique:
received: 20 06 2022
accepted: 31 01 2023
entrez: 24 3 2023
pubmed: 25 3 2023
medline: 25 3 2023
Statut: epublish

Résumé

Safer conception services are needed to minimize HIV transmission among HIV sero-different couples desiring pregnancy. Few studies have evaluated the choices couples make when offered multiple safer conception methods or real-world method acceptability and effectiveness. We piloted a comprehensive safer conception program (Clintrials.gov identifier: NCT03049176) for HIV sero-different couples planning pregnancy in Zimbabwe to measure feasibility, method uptake, acceptability, pregnancy outcome, and HIV transmission. This study was not designed to compare rates of HIV transmission by safer conception method choice but rather to understand choices couples make when seeking to minimize risk of HIV transmission and maximize likelihood of pregnancy. Couples in this prospective, non-randomized study were given a choice of one or more currently available safer conception methods: antiretroviral therapy (ART) with monthly viral load (VL) monitoring for the HIV-positive partner (ART/VL), pre-exposure prophylaxis (PrEP) for the HIV-negative partner, vaginal insemination (VI) for couples with an HIV-positive woman, and semen washing (SW) for couples with an HIV-positive man. Couples were followed monthly for up to 12 months of pregnancy attempts, quarterly during pregnancy, and 12 weeks post-partum. At each visit, data on method use, urine for pregnancy testing, and blood for HIV antibody testing, or viral load if HIV-positive, were obtained. Infants born to HIV-positive women were tested for HIV at 6 and 12 weeks. Between March 2017 and June 2019, 46 individuals from 23 HIV sero-different partnerships were enrolled and followed. At enrollment, all couples chose ART/VL, and all couples chose at least one additional method; 74% chose PrEP, 36% chose SW, and 25% chose VI. During pre-pregnancy follow-up visits, three couples discontinued SW, and one couple discontinued VI; all four of these couples opted for ART/VL plus PrEP. Satisfaction with safer conception methods was high among those who chose ART/VL and PrEP. Twelve couples achieved pregnancy. There were no cases of HIV transmission to partners, and no infants tested positive for HIV. This safer conception program is feasible and acceptable, allowing sero-different couples to safely achieve pregnancy. Sero-different couples in Zimbabwe seek a combination of HIV prevention methods, particularly ART/VL plus PrEP. Trial Registration: Clintrials.gov, NCT03049176.

Identifiants

pubmed: 36963004
doi: 10.1371/journal.pgph.0000796
pii: PGPH-D-22-00850
pmc: PMC10022125
doi:

Banques de données

ClinicalTrials.gov
['NCT03049176']

Types de publication

Journal Article

Langues

eng

Pagination

e0000796

Informations de copyright

Copyright: © 2023 Brown et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Infect Dis. 2016 Jul 1;214(1):55-64
pubmed: 26917574
J Infect Dis. 2012 Dec 1;206(11):1695-705
pubmed: 23066160
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
Lancet HIV. 2019 Jul;6(7):e438-e446
pubmed: 31160268
AIDS Behav. 2012 Jan;16(1):69-78
pubmed: 21656145
HIV Med. 2011 May;12(5):316-21
pubmed: 21205129
Afr Health Sci. 2009 Mar;9(1):2-12
pubmed: 20842236
AIDS Care. 2012;24(4):509-16
pubmed: 22085306
AIDS Behav. 2013 Feb;17(2):471-8
pubmed: 22354359
Lancet. 2008 Jun 28;371(9631):2183-91
pubmed: 18586173
J Acquir Immune Defic Syndr. 2006 Mar;41(3):315-22
pubmed: 16540932
J Infect Dis. 2005 May 1;191(9):1403-9
pubmed: 15809897
BMJ. 2017 Dec 11;359:j5011
pubmed: 29229609
AIDS Behav. 2018 Jun;22(6):1713-1724
pubmed: 28501964
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8
pubmed: 24784763
BMC Public Health. 2010 Sep 21;10:565
pubmed: 20858279
BMC Health Serv Res. 2020 Oct 12;20(1):940
pubmed: 33046066
Front Glob Womens Health. 2020 Dec;1:
pubmed: 33693437
Lancet HIV. 2020 Jan;7(1):e38-e48
pubmed: 31813837
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):775-778
pubmed: 34043612
J Int AIDS Soc. 2017 Mar 8;20(Suppl 1):21271
pubmed: 28361506
PLoS One. 2019 Mar 6;14(3):e0212656
pubmed: 30840672
Fertil Steril. 2016 Mar;105(3):645-655.e2
pubmed: 26688556
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
Sex Transm Infect. 2012 Feb;88(1):51-7
pubmed: 22250180
BMJ Open. 2019 Jul 26;9(7):e027227
pubmed: 31350241
JAMA. 2018 Mar 27;319(12):1261-1268
pubmed: 29584848
Implement Sci. 2021 Apr 15;16(1):41
pubmed: 33858462
HIV Med. 2008 Oct;9(9):681-720
pubmed: 18983476
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
AIDS Behav. 2018 Sep;22(9):2916-2946
pubmed: 29869184
AIDS Educ Prev. 2016 Dec;28(6):524-538
pubmed: 27925487
Drugs. 2019 Aug;79(12):1263-1276
pubmed: 31309457
Am J Obstet Gynecol. 2019 Oct;221(4):347.e1-347.e13
pubmed: 31136732
Reprod Sci. 2021 Jan;28(1):134-143
pubmed: 32734563
Lancet. 2022 May 7;399(10337):1779-1789
pubmed: 35378077
PLoS One. 2008 Jan 09;3(1):e1411
pubmed: 18183292
Nat Med. 2020 May;26(5):655-664
pubmed: 32405065
Lancet. 2006 May 6;367(9521):1487-94
pubmed: 16679161
J Obstet Gynaecol Can. 2012 Jun;34(6):575-590
pubmed: 22673174
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
AIDS Care. 2016;28(3):390-6
pubmed: 26445035
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Health Care Women Int. 2014;35(7-9):990-1009
pubmed: 24901882
AIDS. 2020 Apr 1;34(5):761-776
pubmed: 32167990
J Int AIDS Soc. 2019 Apr;22(4):e25261
pubmed: 30957420
AIDS Rev. 2018;20(3):131-140
pubmed: 30264827
AIDS Care. 2015;27(1):10-6
pubmed: 25105422
AIDS Rev. 2006 Jul-Sep;8(3):158-70
pubmed: 17078486
Lancet Glob Health. 2020 Sep;8(9):e1152-e1161
pubmed: 32710833

Auteurs

Joelle M Brown (JM)

Department of Obstetrics, Gynecology, Reproductive Sciences, University of California, San Francisco, San Francisco, California, United States of America.
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.

Serah Gitome (S)

Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.

Bismark Mataveke (B)

University of Zimbabwe, Harare, Zimbabwe.

Thandiwe Chirenda (T)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Allen Matubu (A)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Gift Chareka (G)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Charles Chasakara (C)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Nyaradzo Mgodi (N)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Caroline Murombedzi (C)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Petina Musara (P)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Tinei Makurumure (T)

Mercy-Care Fertility Centre, Harare, Zimbabwe.

Carolyn Smith Hughes (CS)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.

Elizabeth Bukusi (E)

Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.

Craig R Cohen (CR)

Department of Obstetrics, Gynecology, Reproductive Sciences, University of California, San Francisco, San Francisco, California, United States of America.

Stephen Shiboski (S)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.

Lynae Darbes (L)

Department of Health Behavior and Biological Sciences, University of Michigan, Ann Arbor, Michigan, United States of America.

James G Kahn (JG)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.

George W Rutherford (GW)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.

Z Michael Chirenje (ZM)

Department of Obstetrics, Gynecology, Reproductive Sciences, University of California, San Francisco, San Francisco, California, United States of America.
University of Zimbabwe, Harare, Zimbabwe.
University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Felix Mhlanga (F)

University of Zimbabwe, Harare, Zimbabwe.
University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

Classifications MeSH